FDA approves wider use of new sickle cell gene therapy by end of 2024?

Next disease targeted by Phase 3 CRISPR gene therapy trials by end of 2025

New types of disorders targeted by CRISPR by end of 2024

New clinical trials for CRISPR blindness treatment initiated by mid-2025?

Peer-reviewed study on long-term efficacy of sickle cell gene therapy published in 2024?

Will BlueBird Bio's gene therapy for sickle cell disease receive Medicare coverage by the end of 2024?

Patient count for sickle cell gene therapy by end of 2025

Will major U.S. insurance companies cover gene therapy for sickle cell by mid-2025?

Will more than 500 patients receive the approved gene therapy for sickle cell in the U.S. by end of 2025?

Will gene therapy for sickle cell disease receive FDA approval for commercial use by end of 2025?

Which entity will be the first to announce coverage for BlueBird Bio's gene therapy for sickle cell disease?

Will BlueBird Bio's gene therapy for sickle cell disease be administered to more than 100 patients by the end of Q1 2025?

Will any major insurance company announce coverage for BlueBird Bio's gene therapy for sickle cell disease by the end of 2024?

What percentage of U.S. sickle cell patients will receive gene therapy by end of 2025?

How many countries will approve gene therapy for sickle cell disease by end of 2025?

What will be the cost range of gene therapy for sickle cell in the U.S. by end of 2025?

Which of the following will be the biggest barrier to the widespread adoption of BlueBird Bio's gene therapy for sickle cell disease?

What will be the average cost of BlueBird Bio's gene therapy for sickle cell disease for patients after insurance coverage?